» Articles » PMID: 29793630

Cardiovascular Risk Reduction in Patients With Chronic Kidney Disease: Potential for Targeting Inflammation With Canakinumab

Overview
Date 2018 May 26
PMID 29793630
Citations 9
Authors
Affiliations
Soon will be listed here.
Citing Articles

Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.

Frak W, Dabek B, Balcerczyk-Lis M, Motor J, Radzioch E, Mlynarska E Antioxidants (Basel). 2024; 13(6).

PMID: 38929126 PMC: 11200916. DOI: 10.3390/antiox13060687.


Atorvastatin, etanercept and the nephrogenic cardiac sympathetic remodeling in chronic renal failure rats.

Xu J, Xue Z, Zhang Y, Liu X, Zhang X, Yang X J Geriatr Cardiol. 2024; 21(4):443-457.

PMID: 38800544 PMC: 11112150. DOI: 10.26599/1671-5411.2024.04.007.


Novel Therapeutic Approaches in the Management of Chronic Kidney Disease.

Dabek B, Dybiec J, Frak W, Fularski P, Lisinska W, Radzioch E Biomedicines. 2023; 11(10).

PMID: 37893119 PMC: 10604464. DOI: 10.3390/biomedicines11102746.


Pyroptosis in renal inflammation and fibrosis: current knowledge and clinical significance.

Liu Y, Lei H, Zhang W, Xing Q, Liu R, Wu S Cell Death Dis. 2023; 14(7):472.

PMID: 37500614 PMC: 10374588. DOI: 10.1038/s41419-023-06005-6.


Chronic Kidney Disease as a Comorbidity in Heart Failure.

Szlagor M, Dybiec J, Mlynarska E, Rysz J, Franczyk B Int J Mol Sci. 2023; 24(3).

PMID: 36769308 PMC: 9918100. DOI: 10.3390/ijms24032988.